Loading...
XHKG6821
Market cap3.64bUSD
Dec 23, Last price  
51.50HKD
1D
0.88%
1Q
5.64%
IPO
-80.51%
Name

Asymchem Laboratories Tianjin Co Ltd

Chart & Performance

D1W1MN
XHKG:6821 chart
P/E
7.29
P/S
2.11
EPS
6.63
Div Yield, %
3.77%
Shrs. gr., 5y
2.37%
Rev. gr., 5y
33.65%
Revenues
7.83b
-23.70%
405,691,300424,399,200542,757,593716,207,193830,607,6941,103,194,9521,423,033,4121,834,877,6242,459,985,5333,149,689,6754,638,834,17710,255,325,3927,825,190,298
Net income
2.27b
-31.28%
65,372,50060,251,40074,729,476101,791,578153,545,023252,735,199341,287,654428,295,474553,863,836722,091,3601,069,273,5773,301,635,0192,268,810,444
CFO
3.55b
+8.00%
25,883,50034,384,900105,917,363127,045,751256,994,132278,355,646196,400,310415,060,930600,867,843569,291,589113,150,1213,286,910,7053,549,728,383
Dividend
Jun 13, 20241.9767 HKD/sh
Earnings
Jun 06, 2025

Profile

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
URL
https://www.asymchem.com.cn/
IPO date
Nov 18, 2016
Employees
9,719
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,825,190
-23.70%
10,255,325
121.08%
4,638,834
47.28%
Cost of revenue
4,898,684
6,492,121
3,222,726
Unusual Expense (Income)
NOPBT
2,926,506
3,763,204
1,416,108
NOPBT Margin
37.40%
36.70%
30.53%
Operating Taxes
306,310
430,314
123,694
Tax Rate
10.47%
11.43%
8.73%
NOPAT
2,620,196
3,332,891
1,292,414
Net income
2,268,810
-31.28%
3,301,635
208.77%
1,069,274
48.08%
Dividends
(663,897)
(211,272)
(145,560)
Dividend yield
1.58%
0.39%
0.10%
Proceeds from repurchase of equity
(9,317)
6,008,077
BB yield
0.02%
-4.05%
Debt
Debt current
12,228
28,487
388,609
Long-term debt
212,972
219,719
91,754
Deferred revenue
232,599
168,121
179,049
Other long-term liabilities
1
1
Net debt
(9,657,752)
(7,192,451)
(6,155,293)
Cash flow
Cash from operating activities
3,549,728
3,286,911
113,150
CAPEX
(1,241,610)
Cash from investing activities
(2,890,264)
Cash from financing activities
(542,029)
6,210,707
FCF
2,865,501
1,443,746
(711,918)
Balance
Cash
9,015,765
7,440,656
6,635,656
Long term investments
867,186
Excess cash
9,491,692
6,927,890
6,403,714
Stockholders' equity
8,159,656
6,572,500
12,610,012
Invested Capital
9,701,636
9,311,618
6,731,154
ROIC
27.56%
41.55%
24.42%
ROCE
16.28%
23.56%
10.69%
EV
Common stock shares outstanding
362,430
366,848
341,340
Price
116.12
-21.54%
148.00
-65.98%
435.00
45.42%
Market cap
42,085,346
-22.49%
54,293,554
-63.43%
148,482,728
51.23%
EV
32,457,857
48,097,562
142,327,435
EBITDA
3,390,449
4,104,941
1,630,436
EV/EBITDA
9.57
11.72
87.29
Interest
6,322
10,529
7,328
Interest/NOPBT
0.22%
0.28%
0.52%